- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Long-Term Study Confirms Safety of Metformin in Pregnant Women - Video
|
Overview
Metformin is safe to use during pregnancy to manage diabetes, with no long-term adverse effects on the children born and their mothers for at least 11 years after childbirth, according to research presented at ENDO 2024, the Endocrine Society’s annual meeting.
Metformin, a widely used medication for managing type 2 diabetes, has been the subject of extensive research regarding its safety and efficacy during pregnancy. Traditionally, insulin has been the preferred treatment for managing gestational diabetes; however, emerging evidence indicates that metformin may be just as safe. This long-term data provides reassuring evidence that metformin does not increase the risk of adverse outcomes for both the mother and the fetus compared to insulin.
“Metformin has been extensively used for managing raised blood glucose values in pregnancy for many decades now. It is the only blood glucose-lowering oral medication approved for use in pregnancy,” said Deep Dutta, Director of Endocrinology at CEDAR Superspeciality Healthcare in Dwarka, New Delhi, India.
The researchers cited that data are only available up to roughly five years after childbirth in most studies they found in their analysis. They sought to understand the longer-term effects on mothers with diabetes and their children beyond previously published data.
In their literature review, the researchers analyzed data from 10,117 children-mother pairs taken from seven different study cohorts.
Nine-year-old children born to mothers who took metformin during pregnancy showed similar BMI, waist circumference, dual-energy X-ray absorptiometry (DXA) total body fat, DXA-total body fat percent, DXA-total body fat-free mass, MRI visceral adipose tissue and magnetic-resonance spectroscopy liver fat percentage as children born to mothers who used insulin during pregnancy.
Ultimately, they concluded that taking metformin during pregnancy is as safe as using insulin for lowering blood glucose during pregnancy. Obesity and diabetes in mothers who took metformin during pregnancy were also similar during the 11-year postpartum follow-up period.
“Our study provides us with reassuring data on the long-term safety of metformin use in pregnancy on the children and their mothers,” Dutta said.
Reference: Deep Dutta, Director of Endocrinology at CEDAR Superspeciality Healthcare; Metformin may be as safe as insulin during pregnancy, 11-year data shows; THE ENDOCRINE SOCIETY; ENDO 2024
Speakers
Anshika Mishra is a dedicated scholar pursuing a Masters in Biotechnology, driven by a profound passion for exploring the intersection of science and healthcare. Having embarked on this academic journey with a passion to make meaningful contributions to the medical field, Anshika joined Medical Dialogues in 2023 to further delve into the realms of healthcare journalism.